As shown in Table 2, low mRNA expression of RORα [HER2 negative: HR = 1.51, 95% CI: (1.19–1.91), P = 0.00064; HER2 positive: HR = 1.36 95% CI: (1.04–1.79), P = 0.024] and RORβ [HER2 negative: HR = 1.95, 95% CI: (1.51–2.51), P < 0.0001; HER2 positive: HR = 1.59 95% CI: (1.15–2.19), P = 0.0046] was associated with a better prognosis in both HER2-negative and HER2-positive patients with GC. The gene discussed is ERBB2; the disease is gastric cancer.